Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

Istanbul Medeniyet University

Status: Unknown

Conditions: Mouth and Tooth Diseases; Periodontal Diseases; Gingivitis

Treatments: Drug: undefined

Study type: Observational

Funder types: Other

Identifiers

NCT04946617

9.2.2017-30

Details and patient eligibility

About

Recent studies have shown that while mouthwashes exhibit antimicrobial properties against bacteria and their products, at the same time showing the cytotoxic effect on living cells in the mouth.29 To the best of our knowledge, there is no information about the toxicity effect of these two mouthwashes, which are highly preferred, on antimicrobial peptides secreted from the oral epithelium. Therefore, our aim in this study is to evaluate the effect of chlorhexidine and essential oil mouthwash on hBD2 and LL-37 in saliva.

Full description

Periodontal health continues with a balanced interaction of the oral microflora with the host defense line.

Enrollment: 120 estimated patients

Sex: All

Ages: 25 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. systemically healthy,
2. presence of ≥20 natural teeth,
3. agreement to participate in the study .

Exclusion criteria

1. known systemic illness,
2. smoking habit,
3. pregnancy/ lactation,
4. long-term use of anti-inflammatory drugs.

Trial design

120 participants in 3 patient groups

H group

Description:

healthy periodontium, BOP at \\20 % of the sites and no sites with probing depth (PD) \[3 mm and clinical attachment level (CAL) \[2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38

Treatment:

Drug: undefined

G group

Description:

gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL \[3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);

Treatment:

Drug: undefined

CP group

Description:

chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at \[≥80 % of the proximal sites and radiographic evidence of interproximal bone loss

Treatment:

Drug: undefined